PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma.
- DOI
- 10.1038/s41419-026-08739-5
- Published
- 2026 Apr 15
- Container
- Cell death & disease
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41419-026-08739-5,
title = {PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma.},
author = {Onishi S and Jayamohan S and Chowdhury A and Rivas S and Otani Y and Ertekin C and Bryant JP and Murphy SA and Rivera-Caraballo KA and Walbridge S and Sisay B and Maric D and Elkahloun A and Johnson K and Brown DA and Heiss JD and Shah AH and Lee TJ and Kumbar SG and Yoo JY and Brenner AJ and Kaur B and Sareddy GR and Banasavadi-Siddegowda YK},
year = {2026},
journal = {Cell death \& disease},
doi = {10.1038/s41419-026-08739-5},
url = {https://doi.org/10.1038/s41419-026-08739-5}
}RIS
TY - JOUR TI - PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma. AU - Onishi S AU - Jayamohan S AU - Chowdhury A AU - Rivas S AU - Otani Y AU - Ertekin C AU - Bryant JP AU - Murphy SA AU - Rivera-Caraballo KA AU - Walbridge S AU - Sisay B AU - Maric D AU - Elkahloun A AU - Johnson K AU - Brown DA AU - Heiss JD AU - Shah AH AU - Lee TJ AU - Kumbar SG AU - Yoo JY AU - Brenner AJ AU - Kaur B AU - Sareddy GR AU - Banasavadi-Siddegowda YK PY - 2026 JO - Cell death & disease DO - 10.1038/s41419-026-08739-5 UR - https://doi.org/10.1038/s41419-026-08739-5 ER -
APA
S, O., S, J., A, C., S, R., Y, O., C, E., JP, B., SA, M., KA, R., S, W., B, S., D, M., A, E., K, J., DA, B., JD, H., AH, S., TJ, L., SG, K., JY, Y., AJ, B., B, K., GR, S., & YK, B. (2026). PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma.. Cell death & disease. https://doi.org/10.1038/s41419-026-08739-5
Source records
- pubmed · retrieved 2026-09-26T06:49:59.962Z